STOKStoke Therapeutics, Inc.
Stoke Therapeutics, Inc. (STOK) sells gene therapy for rare neurological disorders, with its lead candidate, zorevunersen, targeting refractory focal epilepsy. The next catalyst is Nov 3, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to maintain cash flow while advancing its pipeline.
- Revenue surged 404.5% YoY to $40.00M, but net income remains deeply negative at -$199.97M.
- Free cash flow (TTM) stands at $1.27M, with a net margin of -499.9%.
- Shareholders’ equity is $352.46M, though the company is still burning through cash at a high rate.
The Read
9% as Q1 2026 results met expectations without new catalysts and cash burn concerns weighed.
The schedule
- Tue3Nov
The earnings release will test whether the company can deliver better-than-expected guidance and revenue, with a focus on the mix of products and cash flow, unlike the last print which underperformed on margin commentary.
- Sun6Dec
The conference data update will test the credibility of STK-001's clinical progress and its potential to meet regulatory expectations, differing from the last update which lacked clear data on efficacy.
- Mon11Jan
The finalization of the Phase 3 trial design and regulatory strategy will test the company's ability to align its trial with FDA expectations, differing from the last print which lacked clarity on the trial's design.
- Tue9Feb
The earnings release will test whether the company can deliver better-than-expected guidance and revenue, with a focus on the mix of products and cash flow, unlike the last print which underperformed on margin commentary.
- Thu6May
The earnings release will test whether the company can deliver better-than-expected guidance and revenue, with a focus on the mix of products and cash flow, unlike the last print which underperformed on margin commentary.
- Thu5Aug
The earnings release will test whether the company can deliver better-than-expected guidance and revenue, with a focus on the mix of products and cash flow, unlike the last print which underperformed on margin commentary.
Past
- Fri18Sep
Actual outcome: Bear · $25.27 at outcome
The stock fell 11.1% following the announcement of a potential secondary equity offering, reflecting investor concerns over dilution and the impact on shareholder value. The offering was seen as a sign of financial pressure, which overshadowed the positive context of securing funding for the Phase 3 trial. The price dropped below the bear floor, confirming the bearish outcome.
Anticipated dilutive financing action to secure long-term funding for the STK-001 Phase 3 pivotal trial execution.
- Thu7May
Actual outcome: Bear · $31.70 at outcome
Stoke Therapeutics reported Q1 2026 earnings that met EPS estimates and provided a pipeline update highlighting durable seizure reductions in four-year open-label data for zorevunersen. Despite remaining on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June, the stock fell below the $33.50 bear floor. The absence of new near-term clinical surprises and the long timeline to mid-2027 Phase 3 data likely led investors to step to the sidelines, driving the bearish price action.
Q1 2026 earnings and a zorevunersen (STK-001) pipeline update on 2026-05-08, with the market reassessing cash runway and Phase 3 readiness around $37.27; a constructive update could support a move toward $40.50, while any acceleration in burn or slippage in timelines could pull the stock back toward $40.50 by 2026-05-14.
- Thu30Apr
Actual outcome: Mixed · $33.28 at outcome
Stoke Therapeutics reported an in-line Q1 EPS loss of $0.79 per share and topped revenue estimates, while highlighting durable seizure reductions in open-label data for its lead therapy, zorevunersen. Despite remaining on track to complete enrollment in its Phase 3 EMPEROR study, the stock ultimately trended downward and breached the $31.00 bear floor in the weeks following the report, reflecting sustained investor concerns over cash burn and capitalization as the company advances its resource-intensive late-stage trials.
Stoke's Q2 earnings print will heavily focus on cash burn rates and capitalization heading into the resource-intensive Phase 3.
- Tue17Mar
Actual outcome: Bull · $33.51 at outcome
Stoke Therapeutics reported Q4 2025 earnings that perfectly met consensus estimates with an EPS of -$0.65. The stock held strong well above the $31.00 bull target, reflecting sustained market confidence in the company's cash runway and the clinical progression of its lead asset, zorevunersen (STK-001), for Dravet syndrome. Despite some insider selling following a massive prior rally, continued institutional accumulation and steady fundamental execution kept the stock firmly in bullish territory.
